05.05.2010 • News

Merck Profit Beats, but 2010 Forecast Cautious

Merck & Co, which recently acquired U.S. rival Schering-Plough, reported better-than-expected first-quarter earnings, but its 2010 profit forecast barely encompassed Wall Street expectations.

Merck earned $299 million, or 9 cents per share, with results hurt by a number of special charges. That compared with $1.43 billion, or 67 cents per share in the year-earlier period.

Excluding special items, Merck earned 83 cents per share. Analysts on average expected 75 cents per share, according to Thomson Reuters I/B/E/S. The company expects 2010 earnings of $3.27 to $3.41 per share, excluding special items. Analysts were expecting $3.41 per share.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.